Delach
Scott Delach, Cambridge, MA US
Patent application number | Description | Published |
---|---|---|
20150313902 | PHARMACEUTICAL COMBINATION COMPRISING BINIMETINIB - A combination of a CDK4/6 inhibitor and a MEK inhibitor for the treatment of diseases such as cancer. | 11-05-2015 |
20160002727 | NOVEL ANDROGEN RECEPTOR MUTATION - Compositions and methods are provided for diagnosis, prognosis and treatment of AR-related diseases, such as prostate diseases, such as prostate cancer, breast cancer, and many other diseases. In particular, a novel and clinically relevant mutation at position 876 of the androgen receptor (AR) has been identified. Drug sensitivity can be predicted and therapeutic regimens can be planned on the basis of the presence or absence of this mutation. Polypeptides comprising, antibodies to, and polynucleotides encoding the mutant AR can be used to identity novel treatments. A double mutation in AR at positions 741 and 877 is also shown to be useful for patient stratification. | 01-07-2016 |
Scott Delach, Waltham, MA US
Patent application number | Description | Published |
---|---|---|
20150322528 | BIOMARKERS ASSOCIATED WITH CDK INHIBITORS - The invention provides methods of monitoring differential gene expression of biomarkers to determine patient sensitivity to Cyclin Dependent kinase inhibitors (CDKi), methods of determining the sensitivity of a cell to a CDKi, methods of treating a patient with a CDKi and methods of screening for candidate CDKi. | 11-12-2015 |
Scott Delach US
Patent application number | Description | Published |
---|---|---|
20160002727 | NOVEL ANDROGEN RECEPTOR MUTATION - Compositions and methods are provided for diagnosis, prognosis and treatment of AR-related diseases, such as prostate diseases, such as prostate cancer, breast cancer, and many other diseases. In particular, a novel and clinically relevant mutation at position 876 of the androgen receptor (AR) has been identified. Drug sensitivity can be predicted and therapeutic regimens can be planned on the basis of the presence or absence of this mutation. Polypeptides comprising, antibodies to, and polynucleotides encoding the mutant AR can be used to identity novel treatments. A double mutation in AR at positions 741 and 877 is also shown to be useful for patient stratification. | 01-07-2016 |